司美格鲁肽用于超重或肥胖合并慢性肾脏病且无糖尿病患者:随机双盲安慰剂对照临床试验
在101例超重或肥胖合并慢性肾脏病且无糖尿病的成人中,随机接受司美格鲁肽2.4 mg每周一次或安慰剂治疗24周。司美格鲁肽组尿白蛋白与肌酐比值较安慰剂组降低52.1%(95%CI -65.5, -33.4;P<0.0001),胃肠道不良事件在司美格鲁肽组更常见(30例 vs 15例)。
要点
- 司美格鲁肽2.4 mg每周一次治疗24周,使尿白蛋白与肌酐比值较安慰剂降低52.1%(95%CI -65.5, -33.4;P<0.0001)。
- 司美格鲁肽组胃肠道不良事件报告30例,安慰剂组15例。
- 在超重/肥胖合并非糖尿病慢性肾脏病患者中,司美格鲁肽治疗24周使白蛋白尿出现有临床意义的降低。
核心结论
- 在超重/肥胖合并非糖尿病慢性肾脏病患者中,司美格鲁肽治疗24周使白蛋白尿出现有临床意义的降低。
研究设计与样本
- 随机双盲安慰剂对照临床试验,纳入估算肾小球滤过率≥25 ml min-1 1.73 m-2且尿白蛋白与肌酐比值≥30且<3,500 mg g-1、体质量指数≥27 kg m-2的成人慢性肾脏病患者。
- 共筛选125例,随机101例至司美格鲁肽组(n=51)或安慰剂组(n=50),司美格鲁肽剂量为2.4 mg每周一次。
- 主要终点为第24周尿白蛋白与肌酐比值较基线的百分比变化,全程监测安全性。
主要发现
- 平均年龄55.8岁(标准差12),女性40例(39.6%),尿白蛋白与肌酐比值中位数251 mg g-1(四分位距100, 584),平均估算肾小球滤过率65.0 ml min-1 1.73 m-2(标准差25),平均体质量指数36.2 kg m-2(标准差5.6)。
- 慢性肾小球肾炎(n=25)和高血压性慢性肾脏病(n=27)是最常见的慢性肾脏病病因。
- 与安慰剂相比,司美格鲁肽治疗24周使尿白蛋白与肌酐比值降低52.1%(95%CI -65.5, -33.4;P<0.0001)。
- 胃肠道不良事件在司美格鲁肽组报告30例,在安慰剂组报告15例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glomerular filtration rate (eGFR) ≥25 ml min-1 1.73 m-2 and urine albumin-to-creatinine ratio (UACR) ≥30 and <3,500 mg g-1) and body mass index ≥27 kg m-2. Participants were randomized to semaglutide 2.4 mg per week or placebo. The primary endpoint was percentage change from baseline in UACR at week 24. Safety was monitored throughout. Overall, 125 participants were screened, of whom 101 were randomized to semaglutide (n = 51) or placebo (n = 50). Mean age was 55.8 (s.d. 12) years; 40 participants (39.6%) were female; median UACR was 251 mg g-1 (interquartile range 100, 584); mean eGFR was 65.0 (s.d. 25) ml min-1 1.73 m-2; and mean body mass index was 36.2 (s.d. 5.6) kg m-2. Chronic glomerulonephritis (n = 25) and hypertensive CKD (n = 27) were the most common CKD etiologies. Treatment for 24 weeks with semaglutide compared to placebo reduced UACR by -52.1% (95% confidence interval -65.5, -33.4; P < 0.0001). Gastrointestinal adverse events were more often reported with semaglutide (n = 30) than with placebo (n = 15). Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. ClinicalTrials.gov registration: NCT04889183 .
引用
- Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2024. PMID: 39455729. doi:10.1038/s41591-024-03327-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。